A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma

Trial Profile

A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Fresolimumab (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 29 Mar 2018 New trial record
    • 29 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top